Literature DB >> 31415903

Exploration of supersaturable lacidipine ternary amorphous solid dispersion for enhanced dissolution and in vivo absorption.

Jian Guan1, Liwei Jin1, Qiaoyu Liu1, Huan Xu1, Haiyang Wu1, Xin Zhang1, Shirui Mao2.   

Abstract

Amorphous solid dispersion stands out among different formulation strategies for the improvement of dissolution rate and bioavailability via generating supersaturated drug solution, which provides a higher solubility than the crystalline counterpart, leading to a promoted intestinal absorption. Soluplus (SOL), termed as the fourth generation of solid dispersion carrier, presented a preferable effect on supersaturation maintaining and bioavailability enhancement for poorly water soluble drugs. However, some binary drug/SOL systems still suffer from insufficient dissolution and unsatisfied in vivo absorption. Thus, taking Lacidipine (LCDP) as a model drug, the aim of this study was to explore a ternary amorphous solid dispersion consisted of SOL and a surfactant to further increasing the dissolution rate and in vivo absorption. First of all, various surfactants were screened via equilibrium solubility enhancement and sodium dodecyl sulfate (SDS) was selected as the most effective candidate. Thereafter, the influence of SOL/SDS and drug/carrier weight ratio on the supersaturation maintaining was investigated. The supersaturated drug solutions were spray dried and the in vitro release, pharmacokinetic behavior as well as physical stability were investigated. It was found that although combination use of SOL and SDS did not present remarkable advantage in supersaturation maintenance in liquid state, 6-7 times higher dissolution rate under non-sink condition was noticed at SOL/SDS ratio 3:1 after spray drying, for LCDP/SOL/SDS based formulation compared to that of the binary LCDP/SOL system, which was maintained even after 92.5% humidity and 60 °C accelerated stability test. Moreover, compared to the LCDP/SOL formulation, approximately 3.3 and 3.7-fold increase in C max and AUC0-∞ was achieved with LCDP/SOL/SDS based formulation. In conclusion, the presented SDS could not only be regarded as solubility enhancer but also dissolution or bioavailability promoter, highlighting its potential application in ternary supersaturable amorphous solid dispersion for further increasing the dissolution and in vivo absorption of poorly water soluble drugs.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amorphous solid dispersion; Lacidipine; Pharmacodynamics; SDS; Soluplus; Stability

Mesh:

Substances:

Year:  2019        PMID: 31415903     DOI: 10.1016/j.ejps.2019.105043

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  4 in total

Review 1.  Supersaturation-Based Drug Delivery Systems: Strategy for Bioavailability Enhancement of Poorly Water-Soluble Drugs.

Authors:  Arvind Sharma; Kanika Arora; Harapriya Mohapatra; Rakesh K Sindhu; Madalin Bulzan; Simona Cavalu; Gulsheen Paneshar; Hosam O Elansary; Ahmed M El-Sabrout; Eman A Mahmoud; Abdullah Alaklabi
Journal:  Molecules       Date:  2022-05-06       Impact factor: 4.927

2.  Antitumor efficacy of CHMFL-KIT-110 solid dispersion in mouse xenograft models of human gastrointestinal stromal tumors.

Authors:  Shengfu Wang; Chunyan Wang; Xiao Wang; Xiang Wang; Lina Huang; Jiajie Kuai; Wei Wei; Xiaorong Lu; Shangxue Yan
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

3.  Mechanism and Improved Dissolution of Glycyrrhetinic Acid Solid Dispersion by Alkalizers.

Authors:  Luning Dong; Yaping Mai; Qiang Liu; Wannian Zhang; Jianhong Yang
Journal:  Pharmaceutics       Date:  2020-01-20       Impact factor: 6.321

4.  Nanostructured Valsartan Microparticles with Enhanced Bioavailability Produced by High-Throughput Electrohydrodynamic Room-Temperature Atomization.

Authors:  Cristina Prieto; Zoran Evtoski; María Pardo-Figuerez; Julia Hrakovsky; Jose M Lagaron
Journal:  Mol Pharm       Date:  2021-06-28       Impact factor: 4.939

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.